Validity, Reliability and Minimum Detectable Changes of 2-Minute Walk , Timed Up and Go, Sit and Stand Test in Patients With Prostate Cancer

Sponsor
Acibadem University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05195190
Collaborator
(none)
80
1
5.9
13.5

Study Details

Study Description

Brief Summary

Prostate cancer is a type of cancer that can occur in men, especially in the fifth and sixth decades of their lives, and various side effects occur depending on the treatments applied in the diagnosed patients. The treatments applied and the decreased level of physical activity also cause a decrease in the quality of life. Recent studies have focused on treatment-related side effects. Before treatment planning, there is a need for clinically validated clinical evaluations specific to prostate cancer patients in order to determine the current status of the patients or to measure the effectiveness of the treatment applied. In addition, tests with a minimal detectable amount of change will be guiding in order to understand that the effectiveness of the applied treatment is significant. The aim of our study is to investigate the validity, reliability and minimal detectable changes of the two-minute walk, sit up and time up and go tests validated in different disease groups for patients with prostate cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: Clinical test

Detailed Description

Performance-based outcome measures are gaining importance in terms of patients' health care. These tests are not specific for any disease or extremity. They are specific tests for walking and getting up from a chair. They evaluate what an individual can do rather than what they perceive the individual can do. Performance measurement tests have a higher level of evidence than just self-reported evaluations.

Time up and go test, two-minute walk test, sit and stand test are the most frequently used tests in the clinic to evaluate functionality. The short duration of the tests and the fact that they do not require equipment provide advantages in the clinical setting.

In the current literature, the validity and reliability of the Time up and go, two-minute walk and sit-up test in elderly prostate cancer patients has not been established. The aim of our study is to investigate the validity and reliability of these tests in elderly prostate cancer patients and to determine their minimum detectable change. Our second aim is to investigate the relationship of these tests we evaluated with the Nottingham Health Profile questionnaire, which evaluates health-related quality of life in elderly cancer patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Validity, Reliability and Minimum Detectable Changes of 2-Minute Walk , Timed Up and Go, Sit and Stand Test in Patients With Prostate Cancer
Actual Study Start Date :
Feb 20, 2022
Anticipated Primary Completion Date :
Jun 20, 2022
Anticipated Study Completion Date :
Aug 20, 2022

Outcome Measures

Primary Outcome Measures

  1. 2 minute walk test -2MWT [2 hours]

    You will be instructed to "walk at a comfortable, usual pace". There will be two attempts for application trial and registration. Practice trial will be used to minimize any potential learning impact. After resting for at least 10 minutes between trials, the distance traveled in 2 minutes will be recorded as 2MWT. The average of both tests will be taken

  2. Time Up and Go Test [2 hours]

    It is the time measured when an individual is standing, walking 3 m straight, returning to the chair, and sitting. In the study, the you will sit comfortably in a chair without back support and arm support. The time for the test will begin as soon as you get up from the chair and will end after you sit in the chair. If the test is less than 10 seconds, it indicates functional independence, and if it is over 30 seconds, it indicates functional dependence.

  3. Sit and Stand Test [2 hours]

    It is used to measure lower extremity strength and evaluate physical capacity. For this study, you will be asked to get up and sit as much as they can within 30 seconds from a chair with a standard 17-inch sitting height and back support.

Secondary Outcome Measures

  1. Nottingham Health Profile -NHP [through study completion, an average of 6 months]

    The Turkish version of the NHP will be used to assess health-related quality of life. NHP is a general quality of life questionnaire that measures the perceived health problems of the individual and the extent to which these problems affect normal daily activities. The questionnaire consists of 38 items and evaluates 6 sub-dimensions related to health status. Energy (3 items), pain (8 items), emotional reactions (9 items), sleep (5 items), social isolation (5 items), and physical activity (8 items). Questions are answered with yes or no. Each section is scored between 0-100. 0 indicates best health, 100 indicates worst health

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
Male
Inclusion Criteria:
  • Receiving or continuing Androgen deprivation therapy for at least 3 months

  • Diagnosed with non-metastatic prostate cancer

  • In the process of radiotherapy or chemoradiotherapy

  • Able to walk without assistive device

  • Patients over 55 years of age

Exclusion Criteria:
  • Diagnosed with metastatic prostate cancer

  • Uncontrollable cardiovascular disease Uncontrollable insulin due to diabetes Individuals with neuromuscular, metabolic disease that may effect physical tests

Contacts and Locations

Locations

Site City State Country Postal Code
1 Acıbadem Mehmet Ali Aydınlar University Istanbul Turkey

Sponsors and Collaborators

  • Acibadem University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Özlem Feyzioğlu, Assistant professor, Acibadem University
ClinicalTrials.gov Identifier:
NCT05195190
Other Study ID Numbers:
  • ATADEK 2021 -21/19
First Posted:
Jan 18, 2022
Last Update Posted:
Jun 7, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2022